amphotericin-b--deoxycholate-drug-combination and Carcinoma--Non-Small-Cell-Lung

A 53-year-old woman with an intraabdominal infection secondary to Candida albicans experienced hyperbilirubinemia after receiving amphotericin B in two different formulations--amphotericin B deoxycholate and amphotericin B lipid complex. Only a few case reports of amphotericin B-induced hyperbilirubinemia have been documented in the literature, each with different patterns of corresponding abnormalities in liver function tests. The unpredictable nature of this adverse effect warrants monitoring of bilirubin levels and liver function at baseline and potentially during therapy with amphotericin B, regardless of formulation, dosage, or duration of therapy.

Topics: Amphotericin B; Antifungal Agents; Candidiasis; Carcinoma, Non-Small-Cell Lung; Deoxycholic Acid; Drug Combinations; Female; Humans; Hyperbilirubinemia; Liver; Middle Aged; Phosphatidylcholines; Phosphatidylglycerols